Novel Alzheimer’s drug gets full FDA approval, though efficacy and risk questioned - The Times of Israel
timesofisrael.comSubmitted by thetimesofisrael5086 in business
Leqembi is first medicine convincingly shown to modestly slow cognitive decline, but some experts say effect too subtle, note dangers